Filtered By:
Specialty: Drugs & Pharmacology
Drug: Warfarin

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 300 results found since Jan 2013.

Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study
ConclusionThe overall rate of bleeding in this cohort was low relative to similar observational studies. The rate of major bleeding was higher in patients prescribed warfarin compared to DOACs, with a similar rate of major bleeding for DOACs and antiplatelet agents. Our findings suggest potential to strategies to reduce bleeding include using DOACs in preference to warfarin, and avoiding multiple antithrombotic therapies in patients with AF.
Source: European Journal of Clinical Pharmacology - September 22, 2017 Category: Drugs & Pharmacology Source Type: research

The safety of edoxaban for treating atrial fibrillation.
Authors: Hammwoehner M, Goette A Abstract INTRODUCTION: Atrial Fibrillation (AF) has a worldwide increasing incidence and prevalence, putting patients at risk for atrial thrombus formation and consecutive thromboembolic events. Morbidity and mortality have become a significant global public health care burden. Thus, there is increasing need for safe and effective medical prophylaxis of thromboembolic events. Edoxaban is the fourth approved non-vitamin K oral anticoagulant (NOAC) that has been introduced into the market for the prophylaxis of stroke or systemic embolism in non valvulär AF patients after dabigatran,...
Source: Expert Opinion on Drug Safety - September 3, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

A retrospective study on the risk factors for bleeding events in warfarin therapy, focusing on renal function
ConclusionsThe present analyses identified age  >  65 years, BMI, ALT, eGFR<30  mL/min/1.73 m2, PT-INR, and concomitant use of antithrombotic drugs as independent risk factors for warfarin-related bleeding. We should pay attention to the risk factors associated with warfarin-related bleeding when prescribing warfarin in patients with renal impairment.
Source: European Journal of Clinical Pharmacology - August 9, 2017 Category: Drugs & Pharmacology Source Type: research

Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies
ConclusionsIn Scotland, adherence to DOAC treatment was good, and switching from DOAC to warfarin was low. However, discontinuation and persistence rates were variable—although treatment interruptions were often temporary.To decrease the inconsistencies in drug utilisation methods and facilitate meaningful study comparison, the use of a coherent framework—using a combination of discontinuation, persistence, and adherence—and the standardisation of measurements is advocated.
Source: Pharmacoepidemiology and Drug Safety - July 28, 2017 Category: Drugs & Pharmacology Authors: Tanja Mueller, Samantha Alvarez ‐Madrazo, Chris Robertson, Marion Bennie Tags: ORIGINAL REPORT Source Type: research

Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015
ConclusionsUse of DOACs for anticoagulation in atrial fibrillation became more prevalent between 2010 and 2015 in Norway, at the expense of warfarin.
Source: European Journal of Clinical Pharmacology - July 22, 2017 Category: Drugs & Pharmacology Source Type: research

Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs
AbstractDirect oral anticoagulants (DOACs) are novel direct-acting medications that are selective for either thrombin or activated factor X. Due to their obvious benefits for patients (fewer interactions, broader therapeutic window, etc.), they are increasingly used as an alternative to warfarin, phenprocoumon, or acenocoumarol. One of the major indications for use of DOACs is stroke prevention in patients with atrial fibrillation (AF). However, interactions still exist, especially in combination with antiarrhythmic drugs (AADs), which are frequently given to AF patients for rhythm or rate control. These interactions are d...
Source: Drug Safety - July 8, 2017 Category: Drugs & Pharmacology Source Type: research

Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs
ConclusionsHigh stroke and bleeding risks favored choices of warfarin or ASA. Among patients receiving NOACs, apixaban was favored for elderly and high-risk patients whereas dabigatran was used in lower risk patients. The inadvertent use of ASA, especially among those with high stroke risks, should be further discouraged.
Source: European Journal of Clinical Pharmacology - June 29, 2017 Category: Drugs & Pharmacology Source Type: research

Dietary implications for patients receiving long-term oral anticoagulation therapy for treatment and prevention of thromboembolic disease.
Authors: Kampouraki E, Kamali F Abstract INTRODUCTION: The effectiveness of oral anticoagulation therapy with warfarin (a vitamin K antagonist) in the treatment of thromboembolic disease, including stroke prophylaxis in patients with atrial fibrillation is well recognised. However, warfarin has a narrow therapeutic window and an unpredictable anticoagulation response, which make it difficult to achieve and maintain optimal anticoagulation. Various dietary factors, including sudden changes in eating patterns, can significantly alter anticoagulation control, thereby potentially exposing patients to the risk of bleedi...
Source: Expert Review of Clinical Pharmacology - June 23, 2017 Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research

Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin.
CONCLUSION: A 63-year-old man on a stable dose of warfarin experienced a decrease in INR values after the initiation of a 12-week course of sofosbuvir and ribavirin for the treatment of chronic HCV infection. PMID: 28596225 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - June 11, 2017 Category: Drugs & Pharmacology Authors: Peterson D, Van Ermen A Tags: Am J Health Syst Pharm Source Type: research

What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review.
CONCLUSIONS: Several factors should be considered when interpreting the results of economic analyses which are based on randomized clinical trial evidence. Real-world data are needed to further assess the clinical and economic consequences of dabigatran relative to warfarin for the prevention of stroke in AF. PMID: 28594478 [PubMed - in process]
Source: Journal of Population Therapeutics and Clinical Pharmacology - June 10, 2017 Category: Drugs & Pharmacology Tags: J Popul Ther Clin Pharmacol Source Type: research

The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Abstract PURPOSE: The goal of this study was to compare the relative efficacy and safety of different types of interventions for stroke prevention in patients with cardiovascular and cerebrovascular diseases. METHODS: This network meta-analysis (NMA) was conducted with a random effects model of Bayesian framework using Stata version 12.0. Odds ratios (ORs) and their credible intervals (CrIs) were applied for the efficacy and safety evaluation of various medical interventions, including aspirin, dipyridamole, ticlopidine, warfarin, and apixaban. In addition, the ranking of probability of every clinical outcome...
Source: Clinical Therapeutics - June 10, 2017 Category: Drugs & Pharmacology Authors: Sun Q, Chang S, Lu S, Zhang Y, Chang Y Tags: Clin Ther Source Type: research

Efficacy and Safety of Uninterrupted Low-Intensity Warfarin for Radiofrequency Catheter Ablation of Atrial Fibrillation in the Elderly: A Pilot Study.
CONCLUSIONS: Uninterrupted low-intensity warfarin for RFCA of AF might be as effective as standard-intensity warfarin in preventing periprocedural thromboembolic complications and might be associated with fewer bleeding events in the elderly. PMID: 28573932 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - June 1, 2017 Category: Drugs & Pharmacology Authors: Xing Y, Xu B, Xu C, Peng F, Yang B, Qiu Y, Sun Y, Wang S, Guo H Tags: Ann Pharmacother Source Type: research

A High HASBLED Score Identifies Poor Warfarin Control in Patients treated for Non ‐Valvular Atrial Fibrillation in Australia and Singapore
This article is protected by copyright. All rights reserved.
Source: Basic and Clinical Pharmacology and Toxicology - June 1, 2017 Category: Drugs & Pharmacology Authors: Nijole Bernaitis, Ching Chi Keong, Chen Liping, Hon Jin Shing, Teo Siew Chong, Tony Badrick, Andrew K. Davey, Shailendra Anoopkumar ‐Dukie Tags: Original Article Source Type: research

Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation.
CONCLUSION: To the best of our knowledge, this is the first observational study finding that concomitant use of clopidogrel reduced the likelihood of DOAC utilization while prescription by a neurologist increased the probability of receiving a DOAC over warfarin in patients with AF.This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page. PMID: 28459661 [PubMed - in process]
Source: Journal of Pharmacy and Pharmaceutical Sciences - May 2, 2017 Category: Drugs & Pharmacology Tags: J Pharm Pharm Sci Source Type: research

The risk of lower gastrointestinal bleeding in low ‐dose aspirin users
ConclusionsThe risk of LGIB was higher in low‐dose aspirin users than in aspirin nonusers in this nationwide cohort. Low‐dose aspirin, NSAIDs, steroids, SSRIs, PPIs and H2RAs were independent risk factors for LGIB.
Source: Alimentary Pharmacology and Therapeutics - April 27, 2017 Category: Drugs & Pharmacology Authors: W. ‐C. Chen, K.‐H. Lin, Y.‐T. Huang, T.‐J. Tsai, W.‐C. Sun, S.‐K. Chuah, D.‐C. Wu, P.‐I. Hsu Tags: Original Article Source Type: research